全文获取类型
收费全文 | 37995篇 |
免费 | 3013篇 |
国内免费 | 1825篇 |
专业分类
耳鼻咽喉 | 460篇 |
儿科学 | 1081篇 |
妇产科学 | 621篇 |
基础医学 | 8532篇 |
口腔科学 | 502篇 |
临床医学 | 2900篇 |
内科学 | 6786篇 |
皮肤病学 | 705篇 |
神经病学 | 2240篇 |
特种医学 | 647篇 |
外国民族医学 | 6篇 |
外科学 | 3242篇 |
综合类 | 5417篇 |
现状与发展 | 6篇 |
预防医学 | 1740篇 |
眼科学 | 653篇 |
药学 | 2235篇 |
3篇 | |
中国医学 | 339篇 |
肿瘤学 | 4718篇 |
出版年
2024年 | 40篇 |
2023年 | 324篇 |
2022年 | 631篇 |
2021年 | 1002篇 |
2020年 | 953篇 |
2019年 | 859篇 |
2018年 | 852篇 |
2017年 | 989篇 |
2016年 | 1083篇 |
2015年 | 1203篇 |
2014年 | 1892篇 |
2013年 | 2179篇 |
2012年 | 2055篇 |
2011年 | 2370篇 |
2010年 | 2022篇 |
2009年 | 2134篇 |
2008年 | 2421篇 |
2007年 | 2513篇 |
2006年 | 2526篇 |
2005年 | 2426篇 |
2004年 | 2000篇 |
2003年 | 1873篇 |
2002年 | 1510篇 |
2001年 | 1364篇 |
2000年 | 1109篇 |
1999年 | 1006篇 |
1998年 | 809篇 |
1997年 | 693篇 |
1996年 | 433篇 |
1995年 | 418篇 |
1994年 | 284篇 |
1993年 | 198篇 |
1992年 | 119篇 |
1991年 | 114篇 |
1990年 | 78篇 |
1989年 | 67篇 |
1988年 | 62篇 |
1987年 | 32篇 |
1986年 | 31篇 |
1985年 | 33篇 |
1984年 | 19篇 |
1983年 | 11篇 |
1982年 | 24篇 |
1981年 | 19篇 |
1980年 | 18篇 |
1979年 | 8篇 |
1978年 | 3篇 |
1977年 | 7篇 |
1976年 | 3篇 |
1970年 | 6篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
992.
Tetsushi Iida Naoko Iida Jun Sese Takehiko Kobayashi 《Genes to cells : devoted to molecular & cellular mechanisms》2021,26(8):555-569
Ribonucleotides incorporated in the genome are a source of endogenous DNA damage and also serve as signals for repair. Although recent advances of ribonucleotide detection by sequencing, the balance between incorporation and repair of ribonucleotides has not been elucidated. Here, we describe a competitive sequencing method, Ribonucleotide Scanning Quantification sequencing (RiSQ-seq), which enables absolute quantification of misincorporated ribonucleotides throughout the genome by background normalization and standard adjustment within a single sample. RiSQ-seq analysis of cells harboring wild-type DNA polymerases revealed that ribonucleotides were incorporated nonuniformly in the genome with a 3′-shifted distribution and preference for GC sequences. Although ribonucleotide profiles in wild-type and repair-deficient mutant strains showed a similar pattern, direct comparison of distinct ribonucleotide levels in the strains by RiSQ-seq enabled evaluation of ribonucleotide excision repair activity at base resolution and revealed the strand bias of repair. The distinct preferences of ribonucleotide incorporation and repair create vulnerable regions associated with indel hotspots, suggesting that repair at sites of ribonucleotide misincorporation serves to maintain genome integrity and that RiSQ-seq can provide an estimate of indel risk. 相似文献
993.
Targeted ultradeep next‐generation sequencing as a method for KIT D816V mutation analysis in mastocytosis 下载免费PDF全文
Thomas Kristensen Sigurd Broesby‐Olsen Hanne Vestergaard Carsten Bindslev‐Jensen Michael Boe Mller 《European journal of haematology》2016,96(4):381-388
Next‐generation sequencing (NGS) is becoming increasingly used for diagnostic mutation analysis in myeloid neoplasms and may also represent a feasible technique in mastocytosis. However, detection of the KIT D816V mutation requires a highly sensitive method in most patients due to the typically low mutation levels. In this study, we established an NGS‐based KIT mutation analysis and analyzed the sensitivity of D816V detection using the Ion Torrent platform. Eighty‐two individual NGS analyses were included in the study. All samples were also analyzed using highly sensitive KIT D816V mutation‐specific qPCR. Measurements of the background level in D816V‐negative samples supported a cutoff for positivity of 0.2% in three different NGS panels. Clinical samples from patients with SM that tested positive using qPCR with a D816V allele burden >0.2% also tested positive using NGS. Samples that tested positive using qPCR with an allele burden <0.2% tested negative using NGS. We thereby demonstrate that caution should be taken when using the potentially very sensitive NGS technique for KIT D816V mutation analysis in mastocytosis, as many patients with SM have D816V mutation levels below the detection limit of NGS. A dedicated and highly sensitive KIT D816V mutation analysis therefore remains important in mastocytosis diagnostics. 相似文献
994.
Katsuyoshi Horibata Akiko Ukai Takafumi Kimoto Tetsuya Suzuki Nagisa Kamoshita Kenichi Masumura Takehiko Nohmi Masamitsu Honma 《Environmental and molecular mutagenesis》2013,54(9):747-754
The recently developed Pig‐a mutation assay is based on flow cytometric enumeration of glycosylphosphatidylinositol (GPI) anchor‐deficient red blood cells caused by a forward mutation in the Pig‐a gene. Because the assay can be conducted in nontransgenic animals and the mutations accumulate with repeat dosing, we believe that the Pig‐a assay could be integrated into repeat‐dose toxicology studies and provides an alternative to transgenic rodent (TGR) mutation assays. The capacity and characteristics of the Pig‐a assay relative to TGR mutation assays, however, are unclear. Here, using transgenic gpt delta mice, we compared the in vivo genotoxicity of single oral doses of N‐ethyl‐N‐nitrosourea (ENU, 40 mg/kg), benzo[a]pyrene (BP, 100 and 200 mg/kg), and 4‐nitroquinoline‐1‐oxide (4NQO, 50 mg/kg) in the Pig‐a (peripheral blood) and gpt (bone marrow and liver) gene mutation assays. Pig‐a assays were conducted at 2, 4, and 7 weeks after the treatment, while gpt assays were conducted on tissues collected at the 7‐week terminal sacrifice. ENU increased both Pig‐a and gpt mutant frequencies (MFs) at all sampling times, and BP increased MFs in both assays but the Pig‐a MFs peaked at 2 weeks and then decreased. Although 4NQO increased gpt MFs in the liver, only weak, nonsignificant increases (two‐ or threefold above control) were detected in the bone marrow in both the Pig‐a and the gpt assay. These findings suggest that further studies are needed to elucidate the kinetics of the Pig‐a mutation assay in order to use it as an alternative to the TGR mutation assay. Environ. Mol. Mutagen. 54:747–754, 2013. © 2013 Wiley Periodicals, Inc. 相似文献
995.
Min S. Kim Yoo R. Kim Nam J. Yoo Sug H. Lee 《APMIS : acta pathologica, microbiologica, et immunologica Scandinavica》2013,121(2):85-94
DNMT3A, a DNA methyltransferase that functions for de novo methylation, is important in development and many cellular processes related to tumorigenesis. Somatic mutations of DNMT3A gene, including recurrent mutations in its Arg‐882, were recently reported in acute myelogenous leukemia (AML), strongly suggesting its role in development of AML. To see whether DNMT3A mutation occurs in other malignancies as well, we analyzed DNMT3A in 916 cancer tissues from 401 hematologic malignancies (AML, acute lymphoblastic leukemias (ALL), multiple myelomas and lymphomas) and 515 carcinomas (lung, breast, prostate, colorectal and gastric carcinomas) using a single‐strand conformation polymorphism (SSCP) assay. We identified DNMT3A mutations, especially the Arg‐882 mutations, in adulthood AML (9.4%). In addition, we found DNMT3A mutations in pre‐B‐ALL and three lung cancers at lower frequencies. Allelic loss of DNMT3A was frequently observed in most cancer types analyzed, including lymphomas (48.1%), gastric cancers (23.5%) and lung cancers (18.3%) irrespective of DNMT3A mutation. Also, loss of DNMT3A expression was common in lung cancers (46.4%), and was associated with the allelic loss. Our data indicate that DNMT3A gene is mutated mainly in AML, but it occurs in other cancers, such as ALL and lung cancer, despite the lower incidences. Also, the data suggest that DNMT3A is altered in many cancer types by various ways, including somatic mutations, allelic loss and loss of expression that might play roles in tumorigenesis. 相似文献
996.
Mitochondrial membrane protein-associated neurodegeneration (MPAN) is an autosomal recessive disorder caused by mutation in the C19orf12 gene. We report a compound heterozygous c.[32C>T];[205G>A;424A>G] (p.[Thr11Met];[Gly69Arg;Lys142Glu]) Czech patient who manifested with right foot dystonia, impaired handwriting, attention deficit, and signs of iron accumulation on brain MRI. Gradually, he developed dysarthria, spastic-dystonic gait, pedes cavi, and atrophy of leg muscles. Additionally, we report demographic parameters, clinical signs, and allelic frequencies of C19orf12 mutations of all published MPAN cases. We compared the most frequent mutations, p.Thr11Met and p.Gly69ArgfsX10; the latter was associated with younger age at onset and more frequent optic atrophy in homozygotes. 相似文献
997.
998.
《Best Practice & Research: Clinical Haematology》2018,31(3):306-314
Peripheral T cell lymphoma (PTCL) is a rare subtype of non-Hodgkin lymphoma. PTCLs are heterogeneous in terms of biology, but generally have more aggressive features and poorer outcomes than aggressive B-cell lymphomas when treated with combination chemotherapy. While the best long-term results are still seen with intensive chemotherapeutic approaches, significant progress has been made with molecular profiling identifying genetic drivers of PTCL that could serve as therapeutic targets. Tailoring therapy to different subtypes of PTCL may lead to more individualized approaches with the hope of improved outcomes. In this paper, we review current therapies for treatment of PTCL, newly identified molecular markers, and the role of emerging therapy and novel combinations of existing agents. 相似文献
999.
Arastoo Saeedi Reza Fardid Mohammad Javad Khoshnoud Elaheh Kazemi Mahmoud Omidi 《Xenobiotica; the fate of foreign compounds in biological systems》2017,47(6):547-552
1.?The prevalence of diabetes and the other metabolic disorders has noticeably increased worldwide. A causal link between increasing risk of type 2 diabetes and exposure to environmental pollutants has been reported.2.?We hypothesized that exposure to methyl tert-butyl ether (MTBE), an oxygenate additive to gasoline would hinder zinc and glucose homeostasis in rats.3.?Male Sprague–Dawley rats received MTBE in drinking water for 90 days. At the end of the treatment, pancreas and blood samples were collected for biochemical and molecular examinations. Expression of four candidate genes, including Insulin1, Insulin2, MT1A, SLC30A8 by Real-Time Quantitative PCR (Q-PCR) as well as biochemical parameters, including fasting blood glucose (FBS), triglycerides (TG), cholesterol (CHO), low-density lipoprotein (LDL), high-density lipoprotein (HDL), copper (Cu2+) and calcium (Ca2+) levels as well as High-sensitive C-reactive protein were assessed as endpoints.4.?This study suggested that MTBE exposure can be associated with disruption in zinc homeostasis and glucose tolerance. 相似文献
1000.
Neurological symptoms in essential thrombocythemia: impact of JAK2V617F mutation and response to therapy 下载免费PDF全文
Andrea Aroldi Caterina Cecchetti Arianna Colombo Leonardo Cattaneo Pietro Enrico Pioltelli Enrico Maria Pogliani Elena Maria Elli 《European journal of haematology》2016,96(6):593-601
Patients with essential thrombocythemia (ET) often suffer from neurological symptoms (NS) not ever resulting from previous thrombotic cerebral events (TCE). We reported NS occurred in 282 patients, in order to identify the factors influencing ET‐related NS in the absence of TCE, and the response to therapy. Overall, 116 of 282 patients (41%) presented NS; 101 of them (87%) reported subjective transient and fluctuating NS, without concurrent TCE, which we defined as ET‐related NS, by frequency: cephalalgia, chronic paresthesias, dizziness or hypotension, visual disturbances, and tinnitus. In univariate analysis, ET‐related NS resulted more frequently in young people (P = 0.017) and in females (P = 0.025). We found a higher prevalence of JAK2V617F mutation in ET‐related NS patients (P = 0.021). In multivariate analysis, gender (P = 0.024) and JAK2V617F mutation (P = 0.041) remained significantly associated with the development of ET‐related NS, with a risk of about four times higher for JAK2V617F‐mutated patients (OR = 3.75). Ninety‐seven of 101 patients with ET‐related NS received an antiplatelet (AP) agent at the time of NS, whereas only selected high‐risk ET‐related NS patients were treated with a cytoreductive drug, according to the published guidelines and similarly to patients without NS. We observed that only 32 of 97 (33%) patients with ET‐related NS achieved a complete response after AP treatment. Among the 65 non‐responder patients, 36 (55.4%) improved NS after the introduction of cytoreductive therapy; therefore, the addition of cytoreductive treatment should be considered in this setting. 相似文献